News
ANNX
7.35
-5.89%
-0.46
Anticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data Readouts
TipRanks · 11h ago
Annexon Shares Rise 18% After 4Q Results Beat Estimates
Annexon shares rise 18% to $8.13 after fourth-quarter results topped analysts' expectations. The biopharmaceutical company reported a loss per share of 36 cents. Wells Fargo raised its price target on Annexon shares to $12 each from $11. The shares of Annexon hit a 52-week high of $9.40.
Dow Jones · 1d ago
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Shares of Cintas Corporation jumped 9.7% to $694.62 on Wednesday. The company reported better-than-expected third-quarter financial results and raised FY24 guidance. PaySign, Inc. Shares jumped 28.2% after the company announced better- than-expected fourth-quarter results. Dow Jones index gained around 300 points in Wednesday's session.
Benzinga · 1d ago
Annexon Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Annexon Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $12
Benzinga · 1d ago
Annexon Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Annexon Price Target Raised to $12.00/Share From $11.00 by Wells Fargo
Dow Jones · 1d ago
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Merck & Company (MRK)
Annexon Biosciences (ANNX) and Merck & Company (MRK) have 2 analysts maintaining Buy ratings on the Healthcare sector. Goldman Sachs analyst Chris Shibutani reiterated a Buy rating on Merck and Company today. The company’s shares closed last week at $130.24.
TipRanks · 1d ago
Optimistic Outlook for Annexon Biosciences Ahead of Pivotal Trial Results
Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Annexon Biosciences (ANNX – Research Report). The associated price target is $16.00. The company is expected to report pivotal Phase 3 trial data for Guillain-Barré syndrome in the second quarter of 2024.
TipRanks · 1d ago
Annexon Price Target Maintained With a $16.00/Share by Needham
Dow Jones · 1d ago
Needham Reiterates Buy on Annexon, Maintains $16 Price Target
Benzinga · 1d ago
Annexon Biosciences: A Strong Buy on Upcoming Clinical Catalysts and Financial Stability
TipRanks · 1d ago
Annexon Biosciences (ANNX) Receives a Buy from TD Cowen
TipRanks · 1d ago
ANNX Stock Earnings: Annexon Beats EPS for Q4 2023
Annexon reported earnings per share of -36 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -48 cents. InvestorPlace Earnings is an automated coverage of quarterly earnings reports. The company's earnings were not reported.
Investorplace · 1d ago
Annexon files for $400M mixed shelf offering
Seeking Alpha · 1d ago
Annexon Biosciences GAAP EPS of -$0.36 beats by $0.09
Annexon Biosciences GAAP EPS of -$0.36 beats by $0.09. Cash, Cash Equivalents, and Short-term Investments of $260M as of December 31, 2023. Q4 GAAP earnings per share of -0.08 beats by 0.08.
Seeking Alpha · 1d ago
Annexon Q4 EPS $(0.36) Beats $(0.48) Estimate
Benzinga · 1d ago
*Annexon: Anticipated Runway Into Mid-2026 >ANNX
Dow Jones · 2d ago
*Annexon 4Q Loss/Shr 36c >ANNX
Dow Jones · 2d ago
More
Webull provides a variety of real-time ANNX stock news. You can receive the latest news about Annexon, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is also evaluating ANX005 for the potential treatment of patients with Huntington’s disease (HD). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications.